Skip to main content

Table 4 Risk factors of HEs aggravation following IVR by Logistic regression analysis

From: Aggravation of retinal hard exudates after intravitreal anti-vascular endothelial growth factor therapy for cystoid macular edema and the risk factors: a retrospective study

Risk factors Univariate Multivariate
OR (95% CI) P-value OR (95% CI) P-value
TG (mmol/L) 1.04 (0.72–1.44) 0.753 1.03 (0.92–1.14) 0.621
TC (mmol/L) 1.08 (1.01–1.28) 0.045* 1.06 (0.65–1.77) 0.320
HDL-C (mmol/L) 0.87 (0.44–1.79) 0.268 0.62 (0.10–1.92) 0.601
LDL-C (mmol/L) 1.37 (1.06–2.01) 0.001** 1.14 (1.03–1.97) 0.021*
Duration of CME(m) 1.98 (1.45–2.23) 0.046* 1.88 (1.01–2.75) 0.012*
CFT (μm) 2.17 (1.59–3.77) 0.344 2.01 (1.42–3.29) 0.384
HEs severity 1.02 (0.85–1.88) 0.319 0.99 (0.51–1.83) 0.337
  1. HEs Hard exudates, IVR Intravitreal injections of ranibizumab, TG Triglycerides, TC Total cholesterol, HDL High-density lipoprotein, LDL Low-density lipoprotein, SRF Subretinal fluid, CME Cystoid macular edema, OR Odds ratio, CI Confidence interval. *, p < 0.05; **, p < 0.01. A p < 0.05 was defined as statistically significant